What it's for (Indications)
- The medicine 'ciprofloxacin + clopidogrel bisulphate' is not a recognized or approved fixed-dose combination product in standard clinical practice.
- Therefore, specific indications for a combined entity do not exist.
- However, if prescribed for concomitant use, the indications for each individual component are distinct.
- * **Ciprofloxacin** is a fluoroquinolone antibiotic indicated for the treatment of various bacterial infections.
- These include, but are not limited to, complicated and uncomplicated urinary tract infections, chronic bacterial prostatitis, acute sinusitis, acute bacterial exacerbations of chronic bronchitis, skin and skin structure infections, bone and joint infections, infectious diarrhea, typhoid fever, and complicated intra-abdominal infections.
- Its use is guided by susceptibility testing and local epidemiological patterns to ensure appropriate antimicrobial coverage.
- * **Clopidogrel Bisulphate** is an antiplatelet agent indicated for the prevention of atherothrombotic events in patients who have experienced a recent myocardial infarction (MI), recent stroke, or have established peripheral arterial disease.
- It is also used in combination with aspirin for patients with acute coronary syndrome (ACS), encompassing unstable angina or non-ST-elevation MI (NSTEMI), and for patients with ST-elevation MI (STEMI) managed medically or with percutaneous coronary intervention (PCI).
- Its primary therapeutic goal is to reduce the incidence of MI, stroke, and cardiovascular death in these high-risk populations.
- The decision to co-administer these drugs should always consider the patient's individual needs and the significant drug interaction profile.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | As 'ciprofloxacin + clopidogrel bisulphate' is not a standard fixed-dose combination, there are no established combined dosage recommendations. Dosages for each medication must be determined individually based on the patient's specific clinical condition, infection severity, renal function, body weight, and other concomitant medications. * **Ciprofloxacin** dosage typically ranges from 250 mg to 750 mg orally, administered every 12 hours, or intravenously. The duration of therapy depends on the type and severity of the infection. For example, uncomplicated urinary tract infections might require 250 mg twice daily for 3 days, while more severe or complicated infections could necessitate 500-750 mg twice daily for longer durations. Renal dose adjustments are often required for patients with impaired kidney function. * **Clopidogrel Bisulphate** dosage generally involves a loading dose followed by a maintenance dose. For acute coronary syndrome, a common loading dose is 300 mg or 600 mg, followed by a maintenance dose of 75 mg once daily. For long-term prevention of atherothrombotic events in patients with a history of MI, stroke, or peripheral arterial disease, the standard maintenance dose is 75 mg once daily. When co-administering these agents, healthcare professionals must meticulously determine the appropriate individual doses while being acutely aware of potential drug-drug interactions and patient-specific factors. |
Safety & Warnings
Common Side Effects
- The side effect profile associated with the concomitant use of ciprofloxacin and clopidogrel encompasses adverse reactions known for each drug individually, as well as potential complications arising from their interaction.
- * **Ciprofloxacin** common side effects include gastrointestinal disturbances (nausea, diarrhea, abdominal pain, vomiting), headache, and dizziness.
- More serious adverse effects, though less common, can include tendinopathy and tendon rupture (particularly Achilles tendon), peripheral neuropathy, central nervous system effects (e.
- g.
- , seizures, confusion, psychosis), QT interval prolongation and cardiac arrhythmias, Clostridioides difficile-associated diarrhea, and photosensitivity reactions.
- Other notable adverse effects include dysglycemia (hypoglycemia or hyperglycemia), hepatotoxicity, and hypersensitivity reactions.
- * **Clopidogrel Bisulphate** common side effects primarily involve bleeding manifestations, such as bruising, epistaxis (nosebleeds), and gastrointestinal bleeding.
- Other less common side effects include diarrhea, abdominal pain, and rash.
- The most significant serious adverse effect is an increased risk of major bleeding events, including intracranial hemorrhage, especially when used with other antithrombotic agents or in patients with an increased bleeding risk.
- A rare but life-threatening adverse event is thrombotic thrombocytopenic purpura (TTP).
- Given the potential for reduced antiplatelet efficacy of clopidogrel due to ciprofloxacin's interaction, patients receiving both drugs should be closely monitored for both general adverse drug reactions and for signs of thrombotic events or unexpected bleeding.
Serious Warnings
- Black Box Warning: None
- Given that 'ciprofloxacin + clopidogrel bisulphate' is not a standard therapeutic combination, the primary warning pertains to the significant and clinically relevant drug-drug interaction when these two medications are co-administered.
- **Significant Drug-Drug Interaction:** Ciprofloxacin is a known inhibitor of cytochrome P450 (CYP) enzymes, particularly CYP1A2 (potent inhibition) and CYP2C19 (moderate inhibition).
- Clopidogrel is a prodrug that requires metabolic activation by CYP enzymes, primarily CYP2C19, to form its active metabolite responsible for antiplatelet activity.
- Concomitant use of ciprofloxacin can inhibit the CYP2C19-mediated activation of clopidogrel, potentially leading to a reduced formation of the active metabolite and, consequently, subtherapeutic antiplatelet effects.
- This diminished antiplatelet efficacy can increase the risk of thrombotic events, such as stent thrombosis, myocardial infarction, or stroke, especially in patients who are critically reliant on clopidogrel's antiplatelet action (e.
- g.
- , those with acute coronary syndromes or recent percutaneous coronary intervention).
- Alternative antibiotic therapy should be strongly considered when a patient is on clopidogrel.
- **General Warnings for Ciprofloxacin (Fluoroquinolones):** * **Black Box Warnings:** Ciprofloxacin carries a black box warning for tendinitis and tendon rupture (especially Achilles tendon), peripheral neuropathy, central nervous system effects (seizures, psychosis), and exacerbation of myasthenia gravis.
- These adverse reactions can be permanent.
- * **Other Warnings:** QT interval prolongation and torsades de pointes, aortic aneurysm rupture or dissection, severe hypersensitivity reactions, hepatotoxicity, dysglycemia (hypo- and hyperglycemia), Clostridioides difficile-associated diarrhea, and photosensitivity.
- **General Warnings for Clopidogrel Bisulphate:** * **Black Box Warning:** Clopidogrel carries a black box warning regarding reduced effectiveness in patients who are 'poor metabolizers' of CYP2C19.
- This genetic variation can lead to lower levels of the active metabolite and reduced antiplatelet activity, increasing the risk of cardiovascular events.
- Genetic testing may be considered for identifying CYP2C19 poor metabolizers in certain clinical situations.
- * **Bleeding Risk:** Clopidogrel significantly increases the risk of bleeding.
- This risk is amplified with concomitant use of other antithrombotic agents (e.
- g.
- , aspirin, heparin, warfarin), non-steroidal anti-inflammatory drugs (NSAIDs), or in patients with pre-existing bleeding disorders.
- Surgical procedures may require temporary discontinuation.
- * **Thrombotic Thrombocytopenic Purpura (TTP):** TTP, sometimes fatal, has been reported with clopidogrel, often within the first two weeks of treatment.
- Immediate treatment with plasma exchange is critical.
- Due to the significant drug interaction and individual risks, the co-prescription of ciprofloxacin and clopidogrel should be undertaken with extreme caution and only when alternative treatment options are not feasible, with stringent monitoring for both thrombotic and bleeding complications.
How it Works (Mechanism of Action)
The 'medicine' ciprofloxacin + clopidogrel bisulphate refers to two distinct pharmacological agents, each possessing a unique mechanism of action.
* **Ciprofloxacin** is a broad-spectrum fluoroquinolone antibiotic. Its bactericidal action is achieved by inhibiting two key bacterial enzymes: DNA gyrase (also known as topoisomerase II) and topoisomerase IV. These enzymes are crucial for bacterial DNA replication, transcription, repair, and recombination processes. DNA gyrase is responsible for supercoiling bacterial DNA, while topoisomerase IV separates daughter DNA molecules during cell division. By targeting both enzymes, ciprofloxacin prevents the unwinding and subsequent rejoining of DNA strands, leading to DNA strand breaks, inhibition of DNA synthesis, and ultimately, bacterial cell death. Its activity is generally concentration-dependent.
* **Clopidogrel Bisulphate** is an antiplatelet prodrug from the thienopyridine class. It requires metabolic activation in the liver by cytochrome P450 (CYP) enzymes, primarily CYP2C19, to form its active thiol metabolite. This active metabolite then selectively and irreversibly binds to the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets. The irreversible binding of clopidogrel's active metabolite to the P2Y12 receptor prevents ADP from binding and activating the receptor. This inhibition of ADP-mediated platelet activation leads to the prevention of activation of the glycoprotein IIb/IIIa complex, which is essential for fibrinogen binding and subsequent platelet aggregation. Because the binding is irreversible, platelets exposed to clopidogrel are inhibited for their entire lifespan (approximately 7-10 days), necessitating the generation of new platelets to restore normal function. This mechanism effectively reduces the formation of arterial thrombi.
Commercial Brands (Alternatives)
No other brands found for this formula.